The administration of fosinopril a new ACE inhibitor with a dose of 10-20 mg/day for 12 weeks reduce systolic blood pressure and diastolic blood pressure significantly, without alternation of heart rate, lipid, carbohydrate and protein metabolisme, and electrolytes are also not distrubed. Side effects are minimal and well tolerated.
This open clinical trial using special protocol for determining the eficacy and safety of Quinapril (10-20 mg) once daily for elderly patients (mean age 70.42 plus/minus 6.63) with hypertension visiting our OPD. Thirty female patients and ten male patients qualifying our inclusion criteria were studied. At the end of the 12 weeks study we conclude that quinapril according to our previous study …
The administration of fosinopril a new ACE inhibitor with a dose of 10-20 mg/day for 12 weeks reduce systolic blood pressure and diastolic blood pressure significantly, without alternation of heart rate, lipid, carbohydrate and protein metabolisme, and electrolytes are also not distrubed. Side effects are minimal and well tolerated.